Biogen acquires sole rights to MS drug from Elan for $3.25B

02/7/2013 | Reuters · Genetic Engineering & Biotechnology News

Biogen Idec agreed to pay Elan $3.25 billion plus future royalties to acquire all rights to multiple sclerosis drug Tysabri, or natalizumab. Tysabri was jointly developed by Biogen and Elan. The deal will strengthen Biogen's presence in the multiple sclerosis drug market as it awaits the FDA's decision on another MS drug, Tecfidera, or dimethyl fumarate.

View Full Article in:

Reuters · Genetic Engineering & Biotechnology News

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Regulatory Affairs Specialist
Becton Dickinson
Franklin Lakes, NJ
Customer Service Director
UCare
Minneapolis, MN
Consumer Directed Health Plan (CDH) Product Offering Manager
Blue Cross Blue Shield MA
Quincy, MA
Behavioral Health Operations Director
UCare
Minneapolis, MN
Chief Quality Officer
UnityPoint Clinic
Des Moines, ID